Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination
Micro-Cap Stock Rises
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.